IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Pilot Trial Of Urinary Nerve Growth Factor (NGF) As Biomarker for Male Lower Urinary Tract Symptoms (LUTS)
This study has been completed.
Sponsor:
The Methodist Hospital System
Collaborator:
Astellas Pharma US, Inc.
Information provided by (Responsible Party):
The Methodist Hospital System
ClinicalTrials.gov Identifier:
NCT01457573
First received: October 20, 2011
Last updated: July 16, 2014
Last verified: July 2014
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
A single center, pilot trial with combination therapy of tamsulosin and solifenacin in 20 men with symptomatic lower urinary tract symptoms (LUTS). Subjects will be evaluated at baseline, 1, 2, and 3 months for urinary NGF, urine creatinine, NGF/CR ratio and patient reported outcomes.
| Condition | Intervention |
|---|---|
| Lower Urinary Tract Symptoms | Drug: Solifenacin (Vesicare) 5 mg orally at the same time. |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Urinary Nerve Growth Factor as a Biomarker for Medical Treatment of Male Lower Urinary Tract Symptoms: A Pilot Trial |
Resource links provided by NLM:
Further study details as provided by The Methodist Hospital System:
Primary Outcome Measures:
- NGF and NGF/Cr ratio-change [ Time Frame: From baseline to week 12 (3 months) ]Urinary Nerve Growth Factor (NGF) and NGF/Cr ratio-change from baseline to week 12.
Secondary Outcome Measures:
- Quality of Life Questionnaires [ Time Frame: Baseline to weeks 4 and 8. ]International Prostate Symptom Score, Patient Perception of Urgency Score (PPIUS), Perception of Bladder Condition (PBC), International Consultation on Incontinence Modular Questionnaire for male LUTS (ICIQ-MLUTS) and the International Consultation on Incontinence Modular Questionnaire LUTS Quality of Life (ICIQ-LUTSqol).
| Enrollment: | 20 |
| Study Start Date: | October 2011 |
| Study Completion Date: | July 2014 |
| Primary Completion Date: | July 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Tamsulosin 0.4 mg + Solifenacin 5 mg
All men will receive morning dosing with Tamsulosin (Flomax) 0.4 mg and Solifenacin (Vesicare) 5 mg orally at the same time.
|
Drug: Solifenacin (Vesicare) 5 mg orally at the same time.
Drug: Tamsulosin 0.4 mg in combination with Solifenacin 5 mg All men will receive morning dosing with Tamsulosin (Flomax) 0.4 mg and Solifenacin (Vesicare) 5 mg orally at the same time. |
Eligibility| Ages Eligible for Study: | 50 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Men > 50 years old with symptomatic LUTS (clinical BPH)
- IPSS > 8
- PSA < 10 (negative biopsies within 6 months for any age-specific PSA elevation suspicious for prostate carcinoma)
- Post void residual urine < 150 mls
- Urinary Flow rate > 15 mL/sec
Exclusion Criteria:
- Neurogenic bladder
- Urinary tract infection, Urinary stone(s), Urinary tract tumor
- Radiation therapy for urologic malignancy or prostate surgery; radiation to pelvic, colon, rectum, prostate, bladder, uterus or ovaries
- Alpha blocker therapy or anticholinergic therapy within 3 months of entry or 5 alpha reductase therapy within 18 months.
- History of cataracts with planned surgery
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01457573
Please refer to this study by its ClinicalTrials.gov identifier: NCT01457573
Locations
| United States, Texas | |
| The Methodist Hospital System | |
| Houston, Texas, United States, 77030 | |
Sponsors and Collaborators
The Methodist Hospital System
Astellas Pharma US, Inc.
Investigators
| Principal Investigator: | Timothy Boone, M.D. | The Methodist Hospital System |
More Information
| Responsible Party: | The Methodist Hospital System |
| ClinicalTrials.gov Identifier: | NCT01457573 History of Changes |
| Other Study ID Numbers: |
IRB# 0711-0124 |
| Study First Received: | October 20, 2011 |
| Last Updated: | July 16, 2014 |
Additional relevant MeSH terms:
|
Lower Urinary Tract Symptoms Urological Manifestations Signs and Symptoms Mitogens Tamsulosin Solifenacin Succinate Mitosis Modulators Molecular Mechanisms of Pharmacological Action Adrenergic alpha-1 Receptor Antagonists |
Adrenergic alpha-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Physiological Effects of Drugs Urological Agents Muscarinic Antagonists Cholinergic Antagonists Cholinergic Agents |
ClinicalTrials.gov processed this record on August 16, 2017